Page 2 - Abstract Session News Today

Investegate announcements from Ipsen Pharma, Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it will be participating in the 37th Annual European Association...

Wide range of research across tumor types underscores Serviers commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022

DGAP-News: Sernova Corp. / Key word(s): Study results/Conference16.12.2021 / 12:05 The issuer is solely responsible for the content of this announcement.LONDON, ONTARIO - December 16, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics...

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic...

Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress - read this article along with other careers information, tips and advice on BioSpace

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care -- New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy -- News provided by Share this article Share this article SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American S...